<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630355</url>
  </required_header>
  <id_info>
    <org_study_id>R-15-091</org_study_id>
    <nct_id>NCT02630355</nct_id>
  </id_info>
  <brief_title>Remote Ischaemic Preconditioning to Prevent Dialysis Induced Cardiac Injury</brief_title>
  <official_title>Randomized Controlled Trial of Remote Ischaemic Preconditioning to Protect Against Dialysis Induced Cardiac Injury in Haemodialysis: Low Vs. High Intensity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academic Medical Organization of Southwestern Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of remote ischaemic preconditioning for the prevention of&#xD;
      dialysis induced cardiac injury. The study uses four arms to test different frequencies of&#xD;
      application to ascertain which, if any, is most successful at reducing dialysis induced&#xD;
      cardiac injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated prematurely after ad-interim analysis for the primary outcome.&#xD;
  </why_stopped>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be a reduction in the number of left ventricular segments undergoing a greater than 30% reduction in longitudinal strain as detected by echocardiography at final study visit</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of segments undergoing &gt;30% reduction in longitudinal strain at intervention, week 1, week 2 and week 3 visits</measure>
    <time_frame>up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between pre and peak global longitudinal strain at intervention, week 1, week 2 and week 3 visits</measure>
    <time_frame>up to 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pre-dialysis global longitudinal strain between baseline and final study visit</measure>
    <time_frame>between 1 and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Troponin-T, Plasma IL-6 and N-Type proBNP at intervention, first follow-up and final visit</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hemodialysis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Inflation of blood pressure cuff in lower limb to 40mmHg for four cycles of 5 minutes inflation and then deflation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inflation of blood pressure cuff in lower limb to 200mmHg for two cycles of 5 minute inflation and then deflation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Intensity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and then deflation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and deflation on weekly basis for four consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Remote Ischaemic Preconditioning</intervention_name>
    <description>Inflation of blood pressure cuff in lower limb</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>High Intensity</arm_group_label>
    <arm_group_label>Low Intensity</arm_group_label>
    <arm_group_label>Standard Intensity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients having haemodialysis treatment at least 3 times per week at a London Health&#xD;
             Sciences Centre facility&#xD;
&#xD;
          2. Male and female, ageâ‰¥16 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not meeting inclusion criteria&#xD;
&#xD;
          2. Exposure to haemodialysis for &lt;90 days prior to recruitment&#xD;
&#xD;
          3. Severe heart failure (New York Heart Association grade IV)&#xD;
&#xD;
          4. Cardiac transplant recipients&#xD;
&#xD;
          5. Mental incapacity to consent&#xD;
&#xD;
          6. Declined to participate&#xD;
&#xD;
          7. Taking cyclosporin&#xD;
&#xD;
          8. Taking ATP-sensitive potassium channel opening or blocking drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western University, Canada</investigator_affiliation>
    <investigator_full_name>Christopher McIntyre</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

